Dr. Kavya Kelagere Mayigegowda, MD

Dr. Kelagere Mayigegowda practices at Alaska Native Medical Center in Anchorage, Alaska, part of Alaska Native Tribal Health Consortium.

Dr. Kelagere Mayigegowda's NPI, 1174032718, was assigned on September 27, 2017. Dr. Kelagere Mayigegowda holds Alaska license 203332.

Dr. Kelagere Mayigegowda's primary practice is Alaska Native Medical Center, at 4315 Diplomacy Dr, Anchorage, AK 99508 in Anchorage Borough. The practice phone is (907) 563-2662.

Dr. Kelagere Mayigegowda's primary practice is Alaska Native Medical Center in Anchorage, Alaska, part of Alaska Native Tribal Health Consortium. Dr. Kelagere Mayigegowda is also affiliated with Alaska Regional Hospital. The medical group on file is Alaska Native Medical Center. Dr. Kelagere Mayigegowda's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kelagere Mayigegowda practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Kelagere Mayigegowda's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Kelagere Mayigegowda's licenses on file in 2 states: Alaska and Texas.

CMS data shows 507 Medicare services from Dr. Kelagere Mayigegowda across 12 procedure codes in 2024, for 291 Medicare patients. Medicare paid $57,458 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 291 Medicare patients who saw Dr. Kelagere Mayigegowda in 2024. The largest group is 65 to 74, with 157 patients. 72% of them have high blood pressure, and 54% have arthritis. 57% are also on Medicaid. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kelagere Mayigegowda's median patient age at 72, with 60% women.

In 2024, Dr. Kelagere Mayigegowda wrote 136 Medicare Part D claims for 68 patients. 68% of them were for generic drugs. CMS names the drug for 83 of them, across 4 drugs with 11 or more claims each, at $321,562 in total drug cost. In 2023, CMS named 33 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Kelagere Mayigegowda for performance year 2024, reported as part of a group. Dr. Kelagere Mayigegowda accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kelagere Mayigegowda as offering telehealth. CMS counts 157 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Kelagere Mayigegowda, more than 86% of the clinicians it reports for that procedure.

CMS Open Payments shows 7 general payments to Dr. Kelagere Mayigegowda from 2 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $564.